Home Stock

Stock Research: Sun Pharmaceuticals

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

Sun Pharmaceuticals

NSI:SUNPHARMA INE044A01036
49
  • Value
    41
  • Growth
    61
  • Safety
    Safety
    71
  • Combined
    56
  • Sentiment
    61
  • 360° View
    360° View
    49
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Sun Pharmaceutical Industries Limited is a specialty generic pharmaceutical company. It operates in the specialty, generics, and consumer healthcare product industries. The company operates globally, with a focus on dermatology, ophthalmology, and onco-dermatology products. In the last fiscal year, the company had a market cap of $47,477 million, profits of $4,726 million, and revenue of $6,153 million with 43,000 employees.

more

ANALYSIS: With an Obermatt 360° View of 49 (better than 49% compared with alternatives), overall professional sentiment and financial characteristics for the stock Sun Pharmaceuticals are below the industry average. The 360° View is based on consolidating four consolidated indicators, with all but one indicator above average for Sun Pharmaceuticals. The consolidated Growth Rank has a good rank of 61, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth, as well as stock returns. This means that growth is higher than for 61% of competitors in the same industry. The consolidated Safety Rank at 71 means that the company has a financing structure that is safer than 71% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. Finally, the consolidated Sentiment Rank has a good rank of 61, which means that professional investors are more optimistic about the stock than for 61% of alternative investment opportunities. But the consolidated Value Rank is less desirable at 41, meaning that the share price of Sun Pharmaceuticals is on the higher side compared with indicators such as revenues, profits, and invested capital. This means the stock price is higher than for 59% of alternative stocks in the same industry. ...read more

more
Strongest Rank Price vs. Sales (P/S)
Weakest Rank Profit Growth
Country India
Industry Pharmaceuticals
Size X-Large
Website sunpharma.com
Index
BSE Sensex
CNX Nifty 50
Sun Pharmaceuticals stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 3-Nov-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
41 33 41 53
Growth
61 81 61 53
Safety
Safety
71 61 43 61
Sentiment
61 97 96 58
360° View
360° View
49 89 82 59
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
53 64 91 74
Opinions Change
67 75 49 52
Pro Holdings
n/a 90 85 16
Market Pulse
51 96 75 65
Sentiment
61 97 96 58
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
41 33 41 53
Growth
61 81 61 53
Safety Safety
71 61 43 61
Combined
56 73 43 63
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
23 19 34 46
Price vs. Earnings (P/E)
31 40 46 50
Price vs. Book (P/B)
34 37 45 56
Dividend Yield
67 48 43 46
Value
41 33 41 53
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
50 56 49 37
Profit Growth
100 57 42 16
Capital Growth
24 80 67 70
Stock Returns
54 75 63 75
Growth
61 81 61 53
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
78 62 50 62
Refinancing
52 40 48 58
Liquidity
75 84 64 61
Safety Safety
71 61 43 61

Similar Stocks

Discover high‑ranked alternatives to Sun Pharmaceuticals and broaden your portfolio horizons.

Gail

NSI:GAIL
Country: India
Industry: Gas Utilities
Size: X-Large
Full Stock Analysis

Gujarat Gas

NSI:GUJGASLTD
Country: India
Industry: Gas Utilities
Size: Large
Full Stock Analysis

Tech Mahindra

NSI:TECHM
Country: India
Industry: IT Consulting & oth. Services
Size: X-Large
Full Stock Analysis

Bandhan Bank

NSI:BANDHANBNK
Country: India
Industry: Regional Banks
Size: Medium
Full Stock Analysis

Frequently Asked
Questions

This stock offers a high growth opportunity with safe financing and positive sentiment. It is typically expensive (low Value Rank), as investors pay a premium for high performance. It is for growth-focused investors comfortable paying a premium for a stock with strong future momentum.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews